Clinical trial
Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV…
NCT00062101 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00062101 |
|---|---|
| Title | Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer |
| Official title | A Phase II Study of OSI 774 (IND Number 63383) in Combination With Celecoxib (Celebrex, Pharmacia) as Second-Line Therapy in Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | erlotinib hydrochloride, celecoxib, laboratory biomarker analysis |
| Enrollment | 80 |
| Start date | Jan 1, 2004 |
| Primary completion | Jan 1, 2006 |
| First posted | Jun 6, 2003 |
| Last update posted | Jun 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: